|
|
|
|
|
|
|
|
CT in ovarian cancer staging: how to review and report with emphasis on abdominal and pelvic disease for surgical planning | Cancer Imaging | Full Text
Abstract
CT
of the abdomen and pelvis is the first line imaging modality for
staging, selecting treatment options and assessing disease response in
ovarian cancer. The staging CT provides disease distribution, disease
burden and is the imaging surrogate for surgico-pathological FIGO
staging. Optimal cyto-reductive surgery offers patients’ the best chance
for disease control or cure, but sub-optimal resection confers no
advantage over chemotherapy and adversely increases the risk of post
surgical complications. Although there is extensive literature comparing
performance of CT against laparoscopy and surgery, for the staging
abdominal and pelvic CT, there are currently no accepted guidelines for
interpretation or routinely used minimum data set templates for
reporting these complex CT scans often with extensive radiological
findings. This review provides a systematic approach for identifying the
important radiological findings and highlighting important sites of
disease within the abdomen and pelvis, which may alter or preclude
surgery at presentation or after adjuvant chemotherapy. The distribution
of sites and volume of disease can be used to categorize patients as
suitable, probably suitable or not suitable for optimal cyto-reductive
surgery. This categorization can potentially assist oncological surgeons
and oncologists as a semi objective assessment tool useful for
selecting patient treatment, streamlining multi disciplinary discussion
and improving the reproducibility and correlation of CT with surgical
findings. The review also highlights sites of disease and complications
of ovarian cancer which should be included as part of the radiological
report as these may require additional surgical input from non
gynaecological surgeons or influence treatment selection.
Background
CT
of the abdomen and pelvis is the standard imaging modality for
preoperative imaging staging at presentation and in distinguishing
between patients suitable for primary cyto-reductive surgery and
patients requiring neoadjuvant chemotherapy prior to surgery. Abdominal
and pelvic peritoneal disease is present in more than 70 % of the women
at the time of presentation. The optimal standard of care for patients
with ovarian cancer, is either primary cyto-reductive surgery or
adjuvant platinum based chemotherapy followed by cyto-reductive surgery [1].....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.